Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,037,590
  • Shares Outstanding, K 66,824
  • Annual Sales, $ 154,580 K
  • Annual Income, $ -50,690 K
  • 36-Month Beta 1.91
  • Price/Sales 28.56
  • Price/Cash Flow N/A
  • Price/Book 12.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.08
  • Number of Estimates 10
  • High Estimate -0.75
  • Low Estimate -1.47
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -191.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.21 +26.33%
on 12/24/18
125.43 -4.11%
on 01/07/19
+21.78 (+22.11%)
since 12/21/18
3-Month
95.21 +26.33%
on 12/24/18
148.72 -19.12%
on 11/02/18
-12.28 (-9.26%)
since 10/22/18
52-Week
50.68 +137.33%
on 02/09/18
176.50 -31.85%
on 06/19/18
+54.63 (+83.21%)
since 01/22/18

Most Recent Stories

More News
Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alphabet Inc. (NASDAQ:GOOGL),...

GOOGL : 1,078.63 (-2.59%)
NGVT : 90.84 (-2.09%)
VCRA : 38.39 (+0.26%)
SRPT : 120.28 (-2.05%)
GSAT : 0.64 (-3.03%)
FLIR : 44.73 (-1.45%)
4 Biotechs That Are Potential Buyouts Post Celgene Deal

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

CELG : 86.00 (-0.31%)
SRPT : 120.28 (-2.05%)
LLY : 117.09 (+0.43%)
INCY : 77.33 (-1.39%)
REGN : 404.75 (-3.36%)
BMY : 49.72 (-0.80%)
ALXN : 114.29 (-2.36%)
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

SRPT : 120.28 (-2.05%)
MYGN : 28.89 (-2.63%)
SMMT : 1.48 (+4.23%)
EDIT : 20.95 (-19.85%)
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy

-- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program,...

SRPT : 120.28 (-2.05%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2018, that were previously approved by the Compensation Committee...

SRPT : 120.28 (-2.05%)
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53

-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne --

SRPT : 120.28 (-2.05%)
Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical Operations

Stoke Therapeutics today announced the addition of two senior leaders who bring substantial experience guiding regulatory strategy and managing clinical development and operations....

SRPT : 120.28 (-2.05%)
Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. Dr. Gray has more...

SRPT : 120.28 (-2.05%)
PIMCO Closed-End Funds Declare Special Year-End Distribution

The Board of Trustees/Directors of the PIMCO closed-end funds (each, a "Fund" and, collectively, the "Funds") has declared a special year-end distribution for certain Fund's common shares as summarized...

IPG : 21.65 (-2.70%)
NGVC : 15.75 (-2.42%)
STC : 43.17 (-0.99%)
ATUS : 18.73 (-1.78%)
RBA : 36.28 (+0.08%)
MHK : 126.72 (+0.08%)
NVCR : 46.62 (+0.37%)
CVSI : 4.6600 (+6.39%)
AC : 39.07 (-3.82%)
BSX : 37.26 (-1.14%)
HON : 139.82 (-1.43%)
POTND : 0.0200 (+32.45%)
PRTT : 1.2500 (-30.56%)
TARSD : 0.2033 (-1.64%)
NKE : 80.75 (+0.37%)
ROIC : 16.78 (-0.59%)
DGX : 86.18 (-0.99%)
EIX : 54.21 (-1.22%)
GARLF : 0.0850 (-2.19%)
MRNA : 15.56 (-6.77%)
MSPC : 0.0002 (unch)
RYAAY : 69.09 (+5.08%)
BA : 357.90 (-1.87%)
BDC : 50.92 (-3.69%)
BC : 48.99 (-2.68%)
OXFD : 14.46 (-2.82%)
NDAQ : 83.40 (+0.31%)
TTOO : 3.60 (-0.28%)
DMAC : 3.60 (-1.10%)
CMCM : 6.50 (-0.76%)
ALGN : 216.16 (-1.79%)
ABM : 35.23 (-2.08%)
RTN : 163.71 (-1.03%)
IESC : 17.02 (+0.71%)
KIDS : 34.06 (+0.06%)
CYL.VN : 0.175 (+12.90%)
FLIR : 44.73 (-1.45%)
NETC.CN : 0.140 (+7.69%)
SLCA : 13.36 (-3.95%)
BANX : 19.85 (+0.61%)
APOG : 33.82 (-1.26%)
RBBN : 5.53 (-2.47%)
SPLIF : 0.2100 (-0.43%)
SO : 47.07 (-0.32%)
SNWV : 0.2170 (-9.01%)
ACB : 6.19 (-3.88%)
CE : 95.73 (-2.13%)
QILFF : 0.1900 (-4.62%)
QILFD : 0.2331 (-29.98%)
MANH : 47.82 (-1.14%)
MKL : 1,035.00 (-3.11%)
HAL : 31.26 (-3.07%)
LZB : 29.68 (-1.49%)
INTC : 48.27 (-1.87%)
APHQF : 11.5700 (-3.05%)
AMZN : 1,632.17 (-3.77%)
ACHC : 28.32 (-2.31%)
TX : 28.26 (-2.18%)
SRPT : 120.28 (-2.05%)
JOUT : 63.52 (-4.95%)
CCAN : 0.2650 (+10.42%)
OBMP : 0.0103 (-6.36%)
ELY : 16.51 (-2.77%)
DY : 57.47 (-3.14%)
HIPH : 0.0530 (-5.19%)
POTN : 0.1058 (-0.94%)
JWN : 47.07 (-0.95%)
SYF : 26.55 (+1.03%)
AQUA : 10.04 (-4.02%)
NWVCF : 1.0517 (+0.16%)
USYNF : 3.1500 (+5.77%)
EMR : 63.01 (-1.05%)
BXE : 0.43 (-2.27%)
HSY : 108.31 (+0.16%)
EW : 168.29 (-0.07%)
SCQBD : 0.7420 (+1.08%)
PTS.TO : 13.11 (+0.15%)
PSX : 93.00 (-2.41%)
MVIS : 0.79 (-1.86%)
PCI : 22.27 (-1.63%)
PCN : 15.42 (+0.72%)
AVT : 41.25 (-2.92%)
MGNX : 11.53 (-6.34%)
ICBK : 18.21 (-4.26%)
DLR : 105.10 (-2.00%)
RHI : 59.76 (-1.82%)
YVR : 2.37 (-1.66%)
PTY : 16.08 (+0.63%)
PDI : 31.12 (-1.27%)
TNXP : 1.93 (-6.31%)
GBT : 47.82 (-2.15%)
QI.VN : 0.290 (-27.50%)
TSRO : 74.96 (+0.03%)
RHP : 76.42 (-0.31%)
NKTR : 44.76 (-3.12%)
GOOG : 1,070.52 (-2.53%)
JBLU : 17.37 (-1.31%)
IGC : 2.49 (unch)
WBT : 13.21 (-0.53%)
WRY.VN : 0.045 (+800.00%)
SAPIF : 28.6410 (-1.69%)
WSO : 144.38 (-0.99%)
LMT : 279.59 (-1.16%)
CMCSA : 34.97 (-3.42%)
HSDT : 7.65 (-8.16%)
GWRE : 84.94 (-0.90%)
CLGX : 36.05 (-1.39%)
FNSR : 21.21 (-2.35%)
SONS : 7.83 (+2.76%)
DEWM : 0.0010 (-9.09%)
SLG : 88.34 (-1.01%)
UPS : 102.68 (+1.06%)
PFN : 9.82 (+0.10%)
KMB : 115.23 (-1.40%)
ANZ.VN : 0.075 (+7.14%)
TAOP : 1.14 (-5.00%)
NSU : 4.48 (-0.88%)
CBDS : 3.5100 (+2.63%)
CTXS : 108.25 (-0.45%)
PCOM : 9.80 (-0.71%)
HTHT : 31.16 (-10.79%)
MAN : 73.13 (-1.76%)
CNK : 39.56 (-3.32%)
AMAT : 34.44 (-3.56%)
FMCC : 2.5100 (+5.46%)
MRK : 75.83 (-0.05%)
ATOS : 1.38 (+2.99%)
WTCRF : 0.0138 (unch)
MLRKF : 0.0835 (-6.07%)
GAZ-UN.VN : 0.600 (unch)
MEOH : 55.91 (-5.17%)
COOL : 17.33 (-0.69%)
SAVE : 58.06 (-2.19%)
PCRX : 40.46 (+1.05%)
RNLSY : 12.7650 (-1.47%)
COL : 141.04 (-0.42%)
COR : 93.21 (-1.15%)
IDXG : 1.03 (-4.63%)
MCD : 184.57 (+1.10%)
ETST : 0.8500 (+19.72%)
QNIIF : 0.7100 (-2.62%)
PII : 85.45 (-3.25%)
AMRS : 3.44 (-4.18%)
SON : 54.85 (+0.07%)
MCK : 125.87 (-0.63%)
APHA : 7.08 (+5.99%)
MCO : 155.48 (-2.46%)
GSKY : 11.00 (-0.09%)
LH : 135.70 (-1.45%)
SAP.TO : 38.67 (-1.60%)
ODFL : 132.90 (-2.73%)
NEU : 401.66 (+0.28%)
ORTX : 12.90 (-3.15%)
BXE.TO : 0.55 (-3.51%)
GWPRF : 11.8700 (+6.23%)
PZN : 8.49 (-3.41%)
RBX.VN : 0.075 (unch)
RNG : 88.78 (-2.71%)
SPG : 173.26 (-0.40%)
TRVN : 0.53 (-3.45%)
AMC : 13.51 (-6.57%)
UTX : 111.06 (-2.49%)
AMD : 19.76 (-4.86%)
NDLS : 7.45 (-1.46%)
MPWR : 120.98 (-3.04%)
KGKG : 0.0580 (+3.94%)
FRO-UN.VN : 0.550 (unch)
DMCAF : 0.2660 (-5.10%)
IRMTF : 11.9721 (-0.40%)
BOX : 19.45 (-2.16%)
IQST : 2.5000 (+25.00%)
ASPS : 23.23 (-2.72%)
HMNY : 0.01 (unch)
ROP : 274.70 (-2.60%)
GOVB : 14.5000 (unch)
PKO : 25.55 (-1.01%)
MYGN : 28.89 (-2.63%)
CRL : 117.59 (-1.36%)
GLPH : 0.0220 (-12.00%)
BXXRF : 0.0051 (-74.50%)
ADTN : 11.78 (-0.93%)
GRNH : 0.0200 (unch)
NS : 25.65 (-2.77%)
LTS : 2.99 (-3.55%)
INT : 23.97 (-1.36%)
INPX : 2.28 (+2.24%)
GSPT : 0.0600 (-50.00%)
MRO.VN : 0.110 (+10.00%)
COST : 212.40 (-0.56%)
EFX : 103.62 (-0.59%)
BMRN : 95.66 (-2.08%)
SPGI : 187.29 (-0.72%)
IGCC : 0.3940 (+3.41%)
PYPL : 89.94 (-1.29%)
LHSIF : 0.7526 (-0.97%)
TDY : 217.39 (-3.44%)
AZPN : 88.93 (-2.24%)
ENW.VN : 1.410 (+2.92%)
DMA.VN : 4.630 (-2.11%)
SNAP : 5.93 (-4.05%)
KSU : 108.45 (-1.87%)
MERC : 14.61 (-1.08%)
DVA : 56.85 (-0.91%)
UNI.VN : 3.700 (-0.27%)
MGI : 2.21 (+0.45%)
IGAP : 0.2310 (-57.92%)
FIT : 6.06 (+0.17%)
RAD : 0.94 (-3.51%)
LDSR : 0.0042 (+7.69%)
CYLYF : 0.1108 (+14.23%)
PMX : 11.38 (-1.04%)
ROBXF : 0.1851 (+262.94%)
BRO : 28.32 (-1.12%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2018, that were previously approved by the Compensation Committee...

SRPT : 120.28 (-2.05%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 124.03
1st Resistance Point 122.16
Last Price 120.28
1st Support Level 118.78
2nd Support Level 117.27

See More

52-Week High 176.50
Fibonacci 61.8% 128.44
Last Price 120.28
Fibonacci 50% 113.59
Fibonacci 38.2% 98.74
52-Week Low 50.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar